A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
SARS-CoV-2 has infected millions of people worldwide. Currently, many clinical trials for drugs against COVID-19 are underway. Viral RNA-dependent RNA polymerase (RdRP) remains the target of choice for prophylactic or curative treatment of COVID-19. Nucleoside analogs are the most promising RdRp inhibitors and have shown effectiveness in vitro as well as in clinical settings. One limitation of such RdRp inhibitors is removal of incorporated nucleoside analogs by SARS-CoV-2 exonuclease (ExoN).doi:10.31219/osf.io/7x5ek fatcat:vh5lvcyshzhqdikee7xzbofrgm